About Jounce Therapeutics (NASDAQ:JNCE)
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. The Company's lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates Inducible T cell CO-Stimulator (ICOS) and is in a Phase II trial.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$37.20 million
Price / Sales13.29
Price / CashN/A
Book Value$5.43 per share
Price / Book2.82
Return on Equity-1.39%
Return on Assets-0.50%
Frequently Asked Questions for Jounce Therapeutics (NASDAQ:JNCE)
What is Jounce Therapeutics' stock symbol?
Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE."
How were Jounce Therapeutics' earnings last quarter?
Jounce Therapeutics, Inc. (NASDAQ:JNCE) released its quarterly earnings results on Monday, November, 13th. The company reported ($0.13) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.25) by $0.12. The business had revenue of $18.10 million for the quarter, compared to the consensus estimate of $20 million. Jounce Therapeutics had a negative net margin of 2.03% and a negative return on equity of 1.39%. The firm's revenue was up 7.1% compared to the same quarter last year. View Jounce Therapeutics' Earnings History.
Where is Jounce Therapeutics' stock going? Where will Jounce Therapeutics' stock price be in 2017?
4 brokerages have issued 12-month price objectives for Jounce Therapeutics' stock. Their predictions range from $28.00 to $30.00. On average, they expect Jounce Therapeutics' stock price to reach $29.00 in the next year. View Analyst Ratings for Jounce Therapeutics.
What are Wall Street analysts saying about Jounce Therapeutics stock?
Here are some recent quotes from research analysts about Jounce Therapeutics stock:
- 1. According to Zacks Investment Research, "Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. It engaged in developing therapies which enable the immune system to attack tumors. The Company's lead product candidate, JTX-2011, is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of certain T cells found in a range of solid tumors. It also developing JTX-4014 for use in future combinations with JTX-2011, as well as for use in combination with other future product candidates. Jounce Therapeutics, Inc. is based in Cambridge, United States. " (11/15/2017)
- 2. Cowen Inc analysts commented, "Jounce provided an interim update from the ICONIC trial." (6/9/2017)
Who are some of Jounce Therapeutics' key competitors?
Some companies that are related to Jounce Therapeutics include Acorda Therapeutics (ACOR), REGENXBIO (RGNX), Amarin Co. plc (AMRN), Omeros Corporation (OMER), Flexion Therapeutics (FLXN), Intra-Cellular Therapies (ITCI), Retrophin (RTRX), Audentes Therapeutics (BOLD), Epizyme (EPZM), Revance Therapeutics (RVNC), CytomX Therapeutics (CTMX), Rhythm Pharmaceuticals (RYTM), Five Prime Therapeutics (FPRX), Raptor Pharmaceutical Corp (RPTP), La Jolla Pharmaceutical Company (LJPC), MacroGenics (MGNX), Akebia Therapeutics (AKBA) and Aclaris Therapeutics (ACRS).
Who are Jounce Therapeutics' key executives?
Jounce Therapeutics' management team includes the folowing people:
- Perry Karsen, Chairman of the Board (Age 62)
- Richard Murray Ph.D., President, Chief Executive Officer, Director (Age 58)
- James P. Allison Ph.D., Co-Founder
- Thomas F. Gajewski M.D. Ph.D., Co-Founder
- Drew Pardoll M.D. Ph.D., Co-Founder
- Padmanee Sharma M.D. Ph.D., Co-Founder
- Kimberlee Cobleigh Drapkin CPA, Chief Financial Officer, Treasurer (Age 49)
- Deborah Law, Chief Scientific Officer
- Elizabeth G. Trehu M.D., Chief Medical Officer (Age 56)
- Luis A. Diaz Jr. M.D., Director
When did Jounce Therapeutics IPO?
(JNCE) raised $76 million in an initial public offering on Friday, January 27th 2017. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.
Who owns Jounce Therapeutics stock?
Jounce Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Brown Advisory Inc. (1.48%), Fosun International Ltd (0.89%), Alyeska Investment Group L.P. (0.81%), Artal Group S.A. (0.62%), Ameriprise Financial Inc. (0.57%) and Conning Inc. (0.39%). Company insiders that own Jounce Therapeutics stock include Celgene Switzerland Llc and John Duncan Higgons. View Institutional Ownership Trends for Jounce Therapeutics.
Who sold Jounce Therapeutics stock? Who is selling Jounce Therapeutics stock?
Who bought Jounce Therapeutics stock? Who is buying Jounce Therapeutics stock?
Jounce Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Fosun International Ltd, Brown Advisory Inc., Alyeska Investment Group L.P., Ameriprise Financial Inc., Parsons Capital Management Inc. RI, Conning Inc., Russell Investments Group Ltd. and First Manhattan Co.. Company insiders that have bought Jounce Therapeutics stock in the last two years include Celgene Switzerland Llc and John Duncan Higgons. View Insider Buying and Selling for Jounce Therapeutics.
How do I buy Jounce Therapeutics stock?
Shares of Jounce Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Jounce Therapeutics' stock price today?
One share of Jounce Therapeutics stock can currently be purchased for approximately $15.33.
How big of a company is Jounce Therapeutics?
Jounce Therapeutics has a market capitalization of $495.62 million and generates $37.20 million in revenue each year. The company earns $-13,700,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Jounce Therapeutics employs 85 workers across the globe.
How can I contact Jounce Therapeutics?
Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3840.
MarketBeat Community Rating for Jounce Therapeutics (JNCE)MarketBeat's community ratings are surveys of what our community members think about Jounce Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History and Estimates Chart for Jounce Therapeutics (NASDAQ:JNCE)
Earnings History by Quarter for Jounce Therapeutics (NASDAQ JNCE)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/13/2017||Q3 2017||($0.25)||($0.13)||$20.00 million||$18.10 million||View||N/A|
|8/9/2017||Q2 2017||($0.15)||($0.11)||$19.94 million||$20.29 million||View||Listen|
|5/9/2017||Q1 2017||($0.09)||($0.02)||$19.71 million||$20.30 million||View||N/A|
|3/10/2017||12/31/2016||$0.04||$0.05||$15.00 million||$20.30 million||View||N/A|
Earnings Estimates for Jounce Therapeutics (NASDAQ:JNCE)
Current Year EPS Consensus Estimate: $-0.77 EPS
Next Year EPS Consensus Estimate: $-1.37 EPS
Dividend History for Jounce Therapeutics (NASDAQ:JNCE)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Jounce Therapeutics (NASDAQ JNCE)
Institutional Ownership Percentage: 40.95%
Insider Trades by Quarter for Jounce Therapeutics (NASDAQ JNCE)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|2/1/2017||Celgene Switzerland Llc||Major Shareholder||Buy||625,000||$16.00||$10,000,000.00|| |
|2/1/2017||John Duncan Higgons||Director||Buy||6,700||$16.00||$107,200.00|| |
Latest Headlines for Jounce Therapeutics (NASDAQ JNCE)
|Jounce Therapeutics, Inc. – Value Analysis (NASDAQ:JNCE) : November 24, 2017|
finance.yahoo.com - November 24 at 5:03 PM
|Jounce Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : JNCE-US : November 23, 2017|
finance.yahoo.com - November 23 at 5:00 PM
|Jounce Therapeutics, Inc. (JNCE) Expected to Post Earnings of -$0.49 Per Share|
www.americanbankingnews.com - November 22 at 9:40 AM
|Can This Tiny Biotech Stock Pay Off Big for Celgene?|
finance.yahoo.com - November 17 at 9:17 AM
|Jounce Therapeutics, Inc. (JNCE) Posts Quarterly Earnings Results, Beats Expectations By $0.12 EPS|
www.americanbankingnews.com - November 14 at 11:24 AM
|Jounce Therapeutics, Inc. (JNCE) Q3 2017 Earnings Conference Call Transcript|
www.fool.com - November 13 at 12:58 PM
|Jounce Therapeutics Reports Third Quarter 2017 Financial Results|
finance.yahoo.com - November 13 at 9:44 AM
|Zacks: Jounce Therapeutics, Inc. (JNCE) Given Consensus Recommendation of "Strong Buy" by Brokerages|
www.americanbankingnews.com - November 11 at 3:28 PM
|Jounce Therapeutics to Present at the Stifel 2017 Healthcare Conference|
finance.yahoo.com - November 11 at 2:44 PM
|Jounce Therapeutics, Inc. (JNCE) Receives Buy Rating from Robert W. Baird|
www.americanbankingnews.com - November 11 at 12:10 PM
|Jounce Therapeutics to Present Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting|
finance.yahoo.com - November 8 at 11:07 AM
|Jounce Therapeutics to Announce Third Quarter 2017 Financial Results and Host Conference Call on Monday, November 13, 2017|
finance.yahoo.com - November 8 at 11:07 AM
|Jounce Therapeutics, Inc. (JNCE) Expected to Post Quarterly Sales of $20.00 Million|
www.americanbankingnews.com - November 4 at 8:22 AM
|-$0.25 EPS Expected for Jounce Therapeutics, Inc. (JNCE) This Quarter|
www.americanbankingnews.com - November 2 at 3:18 PM
|Jounce Therapeutics Is Now Oversold (JNCE)|
www.thestreet.com - October 26 at 3:17 PM
|Jounce Therapeutics Appoints Luis A. Diaz, Jr., M.D., to its Board of Directors|
finance.yahoo.com - October 23 at 7:48 PM
|Jounce Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : JNCE-US : October 19, 2017|
finance.yahoo.com - October 20 at 1:43 AM
|Jounce Therapeutics, Inc. (JNCE) Expected to Announce Quarterly Sales of $20.00 Million|
www.americanbankingnews.com - October 16 at 3:18 AM
|Jounce Therapeutics, Inc. (JNCE) Stock Rating Reaffirmed by Robert W. Baird|
www.americanbankingnews.com - September 18 at 5:08 PM
|Jounce Therapeutics, Inc. (JNCE) Given "Buy" Rating at Robert W. Baird|
www.americanbankingnews.com - September 12 at 9:28 PM
| Analysts Anticipate Jounce Therapeutics, Inc. (JNCE) Will Post Quarterly Sales of $20.00 Million|
www.americanbankingnews.com - September 9 at 7:00 PM
| Brokerages Expect Jounce Therapeutics, Inc. (JNCE) to Post -$0.25 EPS|
www.americanbankingnews.com - September 7 at 2:28 AM
|Jounce Therapeutics to Present at Upcoming Investor Conferences in September|
finance.yahoo.com - August 31 at 6:30 AM
| Jounce Therapeutics, Inc. (JNCE) Given Average Rating of "Strong Buy" by Analysts|
www.americanbankingnews.com - August 30 at 12:18 PM
|Jounce Therapeutics, Inc. – Value Analysis (NASDAQ:JNCE) : August 29, 2017|
finance.yahoo.com - August 29 at 12:48 AM
|$20.00 Million in Sales Expected for Jounce Therapeutics, Inc. (JNCE) This Quarter|
www.americanbankingnews.com - August 21 at 5:48 AM
|Jounce Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : JNCE-US : August 18, 2017|
finance.yahoo.com - August 18 at 7:59 PM
|Jounce Therapeutics (JNCE) Jumps: Stock Moves 7.4% Higher|
finance.yahoo.com - August 18 at 6:07 AM
|Jounce Therapeutics Names Hugh Cole as Chief Business Officer and Head of Corporate Development|
feeds.benzinga.com - August 15 at 8:40 AM
|Jounce Therapeutics Reports Second Quarter 2017 Financial Results|
finance.yahoo.com - August 9 at 10:40 PM
|Jounce Therapeutics, Inc. (JNCE) Issues Earnings Results|
www.americanbankingnews.com - August 9 at 5:34 PM
|Jounce Therapeutics to Announce Second Quarter 2017 Financial Results and Host Conference Call on Wednesday, August 9, 2017|
finance.yahoo.com - August 3 at 1:07 AM
| Jounce Therapeutics, Inc. (NASDAQ:JNCE) Given Consensus Recommendation of "Strong Buy" by Brokerages|
www.americanbankingnews.com - July 29 at 12:44 AM
|Jounce Therapeutics, Inc.'s Lock-Up Period Will Expire on July 26th (NASDAQ:JNCE)|
www.americanbankingnews.com - July 19 at 9:34 AM
|Jounce Therapeutics, Inc. (JNCE) Expected to Announce Quarterly Sales of $20.15 Million|
www.americanbankingnews.com - July 9 at 7:24 AM
|Jounce Therapeutics, Inc. (NASDAQ:JNCE) Expected to Post Earnings of -$0.15 Per Share|
www.americanbankingnews.com - July 8 at 12:10 AM
|4:03 pm Jounce Therapeutics will present preclinical data 'that support the ongoing Phase 1/2 ICONIC trial of JTX-2011' at the AACR Annual Meeting on April 3|
us.rd.yahoo.com - March 23 at 6:40 PM
|JOUNCE THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and|
biz.yahoo.com - March 10 at 7:18 PM
|Coverage initiated on Jounce Therapeutics by JP Morgan, Wells Fargo and Robert W. Baird|
us.rd.yahoo.com - February 22 at 12:30 PM
|IPO Stock News And Analysis: Find Today's Top New Issues|
us.rd.yahoo.com - February 9 at 7:00 PM
Jounce Therapeutics (NASDAQ JNCE) Chart for Saturday, November, 25, 2017